AUTL
Price
$1.78
Change
-$0.07 (-3.78%)
Updated
Aug 15 closing price
Capitalization
473.73M
75 days until earnings call
SCPH
Price
$4.60
Change
-$0.35 (-7.07%)
Updated
Aug 15 closing price
Capitalization
245.17M
81 days until earnings call
Interact to see
Advertisement

AUTL vs SCPH

Header iconAUTL vs SCPH Comparison
Open Charts AUTL vs SCPHBanner chart's image
Autolus Therapeutics
Price$1.78
Change-$0.07 (-3.78%)
Volume$12.16M
Capitalization473.73M
scPharmaceuticals
Price$4.60
Change-$0.35 (-7.07%)
Volume$230.16K
Capitalization245.17M
AUTL vs SCPH Comparison Chart in %
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. SCPH commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and SCPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (AUTL: $1.78 vs. SCPH: $4.60)
Brand notoriety: AUTL and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 608% vs. SCPH: 71%
Market capitalization -- AUTL: $473.73M vs. SCPH: $245.17M
AUTL [@Biotechnology] is valued at $473.73M. SCPH’s [@Biotechnology] market capitalization is $245.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, both AUTL and SCPH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish while SCPH’s TA Score has 5 bullish TA indicator(s).

  • AUTL’s TA Score: 6 bullish, 5 bearish.
  • SCPH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both AUTL and SCPH are a good buy in the short-term.

Price Growth

AUTL (@Biotechnology) experienced а -23.61% price change this week, while SCPH (@Biotechnology) price change was -0.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

AUTL is expected to report earnings on Oct 30, 2025.

SCPH is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($474M) has a higher market cap than SCPH($245M). SCPH YTD gains are higher at: 29.944 vs. AUTL (-24.255). SCPH has higher annual earnings (EBITDA): -83.9M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. SCPH (57.5M). SCPH has less debt than AUTL: SCPH (52.4M) vs AUTL (57.7M). SCPH has higher revenues than AUTL: SCPH (42M) vs AUTL (9.01M).
AUTLSCPHAUTL / SCPH
Capitalization474M245M193%
EBITDA-226.02M-83.9M269%
Gain YTD-24.25529.944-81%
P/E RatioN/AN/A-
Revenue9.01M42M21%
Total Cash517M57.5M899%
Total Debt57.7M52.4M110%
FUNDAMENTALS RATINGS
AUTL vs SCPH: Fundamental Ratings
AUTL
SCPH
OUTLOOK RATING
1..100
5273
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6340
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for SCPH (57) in the Pharmaceuticals Major industry. This means that AUTL’s stock grew somewhat faster than SCPH’s over the last 12 months.

AUTL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that AUTL’s stock grew similarly to SCPH’s over the last 12 months.

AUTL's SMR Rating (96) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that AUTL’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as AUTL (63) in the Biotechnology industry. This means that SCPH’s stock grew similarly to AUTL’s over the last 12 months.

SCPH's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AUTL (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLSCPH
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 25 days ago
82%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASCQX17.10N/A
N/A
American Century Small Company I
NMVLX12.39N/A
N/A
Nuance Mid Cap Value Institutional
ERLVX26.79N/A
N/A
Eaton Vance Large-Cap Value R6
FIQWX17.75N/A
N/A
Fidelity Advisor Strategic Div & Inc Z
MGKQX14.54N/A
N/A
Morgan Stanley Global Permanence R6

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with OCUL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
-3.78%
OCUL - AUTL
49%
Loosely correlated
-0.24%
CRSP - AUTL
45%
Loosely correlated
+1.55%
LRMR - AUTL
44%
Loosely correlated
-5.87%
SCPH - AUTL
43%
Loosely correlated
-7.07%
ERAS - AUTL
43%
Loosely correlated
+4.46%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AUTL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AUTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-7.07%
AUTL - SCPH
45%
Loosely correlated
-3.78%
BEAM - SCPH
42%
Loosely correlated
+1.08%
IPSC - SCPH
41%
Loosely correlated
+2.15%
OCUL - SCPH
41%
Loosely correlated
-0.24%
CRSP - SCPH
40%
Loosely correlated
+1.55%
More